Japanese encephalitis vaccine - VABIOTECH

Drug Profile

Japanese encephalitis vaccine - VABIOTECH

Alternative Names: BR-209; JACEVAX; Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inviragen
  • Developer VABIOTECH
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Japanese encephalitis

Most Recent Events

  • 18 Sep 2017 National Institute of Hygiene and Epidemiology plans the JECEVAX-3 phase III trial for Japanese Encephalitis (In infants, In children) in Vietnam (NCT03282370)
  • 02 Jun 2017 National Institute of Hygiene and Epidemiology, Vietnam, Ministry of Science and Technology, Vietnam and VABIOTECH initiate a phase II trial in Japanese encephalitis (Prevention, In infants) in Vietnam (SC) (NCT03204227)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Japanese encephalitis(Prevention) in Vietnam (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top